newsflaps

FDA Delays Approval Decision for Lilly’s Alzheimer’s Drug, Raising Questions

Controversial New Class of Alzheimer’s Drugs Raises Questions

The Food and Drug Administration (FDA) has postponed its decision on the approval of Eli Lilly’s experimental Alzheimer’s drug, donanemab. The drug, which showed promising results in late-stage clinical trials, was expected to receive a decision from the FDA soon.

In the clinical trials, donanemab demonstrated a 29% reduction in the progression of Alzheimer’s after 18 months compared to a placebo. These results were similar to those seen with Leqembi, another approved Alzheimer’s drug.

The FDA’s decision to delay the approval came as a surprise to many, as it was initially expected to make a final decision without further input. However, the FDA has now requested input from its independent advisory committee to better understand the safety and effectiveness of the drug.

Eli Lilly stated that the FDA wants to “further understand topics” related to the drug before making a final decision. The date for the advisory committee meeting has not been set yet.

If approved, donanemab would have become the third drug in the United States aimed at slowing the progression of Alzheimer’s disease. The other two drugs in this class are Leqembi, developed by Eisai and Biogen, and Aduhelm, developed by Biogen.

Alzheimer’s disease affects a significant number of Americans, with an estimated 6.7 million individuals aged 65 and older living with the disease in 2023, according to the Alzheimer’s Association.

All three drugs under consideration are monoclonal antibodies that target amyloid, a hallmark of Alzheimer’s disease, in the brain.

Alzheimer’s drugs, despite showing modest effectiveness in slowing the disease in clinical trials, have been plagued by concerns over potentially life-threatening side effects, such as brain swelling and bleeding. This particular group of medications has long been a subject of controversy and scrutiny.

In 2021, Biogen’s Aduhelm received an accelerated version of approval, despite being initially rejected by the FDA advisory committee due to insufficient evidence of its effectiveness in slowing the disease. The approval process for Aduhelm was later found to have irregularities, according to an 18-month congressional investigation. The FDA’s decision to grant approval came under intense criticism, as it was deemed to be inconsistent with the agency’s own standards.

Furthermore, the initial cost of Aduhelm, which stood at $56,000 per year, raised concerns about its affordability and potential impact on Medicare premiums. To address these concerns, the company eventually reduced the cost by half. However, under the accelerated approval, Medicare coverage is limited to individuals enrolled in clinical trials, and the drug was never granted full approval by the FDA.

Earlier this year, the company made the decision to withdraw the drug from the market, further highlighting the uncertainties and challenges surrounding these Alzheimer’s medications.

The safety concerns associated with these drugs, coupled with the controversies surrounding their approval and access, have prompted a closer examination of their overall benefit-risk profile. The medical community and regulatory agencies are reevaluating the evidence and considering the real-world implications of these medications for patients.

Developing effective treatments for Alzheimer’s disease remains an ongoing struggle, as researchers and healthcare professionals seek interventions that can truly make a difference in the lives of individuals affected by this debilitating condition. Balancing the need for innovative therapies with rigorous safety evaluations is crucial to ensure that patients receive the best possible care.

As the discussions continue and further research unfolds, it is hoped that clearer guidelines and standards will be established to guide the development and approval of Alzheimer’s drugs. The ultimate goal is to provide safe and effective treatments while maintaining the highest level of patient safety and well-being.

Stay tuned Newsflaps to update more news

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top